Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918578 | 0.98 | CXCR4 (0.46) | CXCR4ALDH1A1CXCL12HRH4HRH3 | |
| SCHEMBL21518374 | 0.98 | CXCR4 (0.46) | CXCR4ALDH1A1CXCL12HRH4HRH3 | |
| SCHEMBL37872 | 0.98 | CXCR4 (0.46) | CXCR4ALDH1A1CXCL12HRH4HRH3 | |
| Ammonia Solution, Strong SCHEMBL4735488 | 0.96 | CXCR4 (0.45) | CXCR4ALDH1A1CXCL12HRH4HRH3 | |
| Phosphine SCHEMBL28328787 | 0.96 | CXCR4 (0.45) | CXCR4ALDH1A1CXCL12HRH4HRH3 | |
| SCHEMBL31100384 | 0.96 | CXCR4 (0.45) | CXCR4ALDH1A1CXCL12HRH4HRH3 | |
| SCHEMBL3857080 | 0.96 | CXCR4 (0.45) | CXCR4ALDH1A1CXCL12HRH4HRH3 | |
| SCHEMBL21518383 | 0.96 | CXCR4 (0.44) | CXCR4ALDH1A1CXCL12HRH4HRH3 | |
| SCHEMBL918238 | 0.96 | S1PR4 (0.41) | CXCR4ALDH1A1CXCL12HRH4HRH3 | |
| Phosphine SCHEMBL28327588 | 0.94 | CXCR4 (0.44) | CXCR4ALDH1A1CXCL12HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4107198-B1 | POLYISOCYANATE PREPARATIONS | COVESTRO DEUTSCHLAND AG (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-3560975-B2 | IONICALLY HYDROPHILIZED POLYISOCYANATES AND ANTIOXIDANTS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-12-06 | — | — | EP | disclosed |
| EP-3724251-B2 | IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-11-22 | — | — | EP | disclosed |
| EP-3851472-B1 | IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-20230080775-A1 | POLYISOCYANATE PREPARATIONS | COVESTRO DEUTSCHLAND AG (DE) | 2023-03-16 | — | — | US | disclosed |
| EP-4107198-A1 | POLYISOCYANATE PREPARATIONS | Covestro Deutschland AG (DE) | 2022-12-28 | — | — | EP | disclosed |
| CN-110396165-B | Ionically hydrophilicized polyisocyanates and antioxidants | 科思创德国股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-112041369-B | Ionically hydrophilicized polyisocyanates, water content | 科思创知识产权两合公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-115066445-A | Polyisocyanate formulations | 科思创德国股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-113651944-B | Ionically hydrophilicized polyisocyanates having improved drying properties | 科思创知识产权两合公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| CN-1839117-A | Improved drug candidates and methods for their preparation | NEUROCHEM INTERNAT LTD (CH) | 2006-09-27 | — | — | CN | disclosed |
| US-20060135403-A1 | Therapeutic formulations for the treatment of beta-amyloid related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-22 | — | — | US | disclosed |
| EP-1646659-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | Neurochem (International) Limited (CH) | 2006-04-19 | — | — | EP | disclosed |
| EP-1644325-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2005-05-05 | — | — | US | disclosed |
| WO-2004113275-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113391-A2 | IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135403-A1 | Therapeutic formulations for the treatment of beta-amyloid related diseases | APP, IAPP, BACE1 | CXCR4 2616/4885ALDH1A1 4695/4885CXCL12 901/4885 |
| US-20050143462-A1 | Pharmaceutical drug candidates and methods for preparation thereof | MPST, TTR, STS | CXCR4 3577/4885ALDH1A1 78/4885CXCL12 502/4885 |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | CXCR4 2873/4885ALDH1A1 2989/4885CXCL12 2139/4885 |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | CXCR4 2873/4885ALDH1A1 2989/4885CXCL12 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.